FDA grants priority review to CorMedix's Rezzayo for fungal disease prevention
CRMD•The FDA granted priority review to CorMedix's application for Rezzayo to prevent invasive fungal disease, with a decision targeted for the first quarter of 2027. A potential promotional launch is targeted for the second half of 2027, subject to approval.
1. Review and potential launch
The FDA granted priority review to CorMedix's application for Rezzayo to prevent invasive fungal disease. A decision is targeted for the first quarter of 2027, and a potential promotional launch is targeted for the second half of 2027, subject to approval.
